Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: Metallomics. 2009 Jan 1;1(4):280–291. doi: 10.1039/b907567d

Figure 1.

Figure 1

Chemical structures of platinum anticancer agents. Cisplatin, carboplatin, and oxaliplatin are FDA-approved for chemotherapy use in the United States. Satraplatin was the first Pt(IV) complex to reach Phase III clinical trials as an orally available platinum compound. cDPCP is a non-classical, monofunctional platinum complex with anti-tumor activity in colorectal cancer cells that inhibits transcription in vitro.